Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

被引:58
作者
Bymaster, FP
Carter, PA
Peters, SC
Zhang, W
Ward, JS
Mitch, CH
Calligaro, DO
Whitesitt, CA
DeLapp, N
Shannon, HE
Rimvall, K
Jeppesen, L
Sheardown, MJ
Fink-Jensen, A
Sauerberg, P
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Lilly Neurosci Res, Indianapolis, IN 46285 USA
[2] Novo Nordisk AS, Hlth Care Discovery, DK-2760 Malov, Denmark
关键词
xanomeline; Alzheimer's disease; phosphoinositide hydrolysis; milameline; muscarinic receptor; muscarinic agonist; acetylcholine;
D O I
10.1016/S0006-8993(98)00267-4
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Activation of muscarinic mi receptors which are coupled to the phosphoinositide (PI) second messenger transduction system is the initial objective of cholinergic replacement therapy in Alzheimer's disease. Thus, we evaluated the ability of the selective muscarinic receptor agonist (SMRA) xanomeline to stimulate in vivo phosphoinositide (PI) hydrolysis and compared it to a number of direct acting muscarinic agonists, two cholinesterase inhibitors and a putative m1 agonist/muscarinic m2 antagonist. Using a radiometric technique, it was determined that administration of xanomeline robustly stimulated in vivo PI hydrolysis and the effect was blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. The non-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-aceclidine, but not the less active isomer R-aceclidine, also effectively stimulated PI hydrolysis in mice. Amongst the putative m1 agonists, thiopilocarpine, hexylthio-TZTP as well as xanomeline effectively stimulated PI hydrolysis, but milameline, WAL 2014, SKB 202026 and PD 142505 did not significantly alter PI hydrolysis. Furthermore, WAL 2014 and SKB 202026 inhibited agonist-induced PI stimulation, suggesting that they act as antagonists at PI-coupled receptors in vivo. The cholinesterase inhibitors, tacrine and physostigmine, and the mixed muscarinic m1 agonist/m2 antagonist LU25-109 did not activate in vive PI hydrolysis. Xanomeline, hexylthio-TZTP and thiopilocarpine were relatively free of cholinergic side effects, whereas milameline, WAL 2014 and SKB 202026 produced non-selective effects. Therefore, these data demonstrate that xanomeline selectively activates in vive PI hydrolysis, consistent with activation of biochemical processes involved in memory and cognition and xanomeline's beneficial clinical effects on cognition in Alzheimers patients. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:179 / 190
页数:12
相关论文
共 52 条
[1]
PHASE-I CLINICAL-TRIALS WITH WAL-2014, A NEW MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE [J].
ADAMUS, WS ;
LEONARD, JP ;
TROGER, W .
LIFE SCIENCES, 1995, 56 (11-12) :883-890
[2]
THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[3]
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[4]
IDENTIFICATION OF A FAMILY OF MUSCARINIC ACETYLCHOLINE-RECEPTOR GENES [J].
BONNER, TI ;
BUCKLEY, NJ ;
YOUNG, AC ;
BRANN, MR .
SCIENCE, 1987, 237 (4814) :527-532
[5]
BRANN MR, 1987, MOL PHARMACOL, V32, P450
[6]
A NOVEL AND SELECTIVE CLASS OF AZABICYCLIC MUSCARINIC AGONISTS INCORPORATING AN N-METHOXY IMIDOYL HALIDE OR NITRILE FUNCTIONALITY [J].
BROMIDGE, SM ;
BROWN, F ;
CASSIDY, F ;
CLARK, MSG ;
DABBS, S ;
HAWKINS, J ;
LOUDON, JM ;
ORLEK, BS ;
RILEY, GJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (08) :791-796
[7]
BROMIDGE SM, 1992, J CHEM SOC, P2189
[8]
BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646
[9]
Bymaster F. P., 1993, Society for Neuroscience Abstracts, V19, P461
[10]
Bymaster FP, 1997, DRUG DEVELOP RES, V40, P158, DOI 10.1002/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO